Introduction
Large monoallelic deletions have been among the most challenging molecular lesions to study in cancer. In some cases, a large hemizygous deletion of one allele is accompanied by mutation, microdeletion or epigenetic silencing of a key gene on the other allele, conforming to the 'two-hit' model of tumor suppressor genes. 1, 2 In other recurrent deletions in cancer, the other chromosomal allele appears to be entirely intact, raising the possibility that haploinsufficiency for one or more genes is pathogenic. 3 RNA interference is a transforming technology for the functional characterization of deletions in cancer, modeling hemizygous or homozygous inactivation depending on the efficacy of knockdown. 4, 5 The development of short hairpin RNA (shRNA) lentiviral expression vectors enables the use of RNA interference in both quiescent and proliferating progenitor cells. 6, 7 The 5q deletion in myelodysplastic syndrome (MDS) is an ideal test case for an RNA interference-based functional screen, because this deletion is associated with a well-defined clinical phenotype, the 5qÀ syndrome, that can be recapitulated in vitro.
The 5qÀ syndrome was reported in 1974 by Van den Berghe et al. 8 as the first hematologic disorder associated with a specific chromosomal deletion. The clinical features have been refined in larger patient series, and the World Health Organization classification of MDS now recognizes the 5qÀ syndrome as a distinct entity, the only subtype defined by a molecular abnormality (Table 1) . [9] [10] [11] [12] [13] [14] [15] [16] [17] Characteristic features of the 5qÀ syndrome include a severe macrocytic anemia, a normal or elevated platelet count with hypolobated micromegakaryocytes and a relatively low rate of progression to acute myelogenous leukemia (AML; 5-16% in the 5qÀ syndrome compared with 30-45% in other types of MDS). 9, 10, 13, 14 The majority of patients with 5q deletions do not have the particular constellation of symptoms that constitute the 5qÀ syndrome. Secondary MDS due to prior treatment with alkylating agents induce 5q or 7q deletions in 90% of cases, and secondary MDS with 5q deletions is associated with a shorter survival than the 5qÀ syndrome. Similarly, transformation to AML is more common in patients with 5q deletions and either treatment-related MDS or MDS with at least one additional cytogenetic abnormality. 14, 18, 19 The search for genes on 5q that contribute to MDS has been ongoing for decades. An important series of studies delineated two common deleted regions (CDRs) on 5q. 9, 10, [20] [21] [22] Functional studies, including both the systematic examination of each gene within a CDR and the investigation of specific candidate genes, are now identifying the roles for individual genes in the pathogenesis of MDS.
Architecture of 5q deletions in MDS
Two CDRs have been identified in 5q, indicating the presence of critical genes within these loci (Figure 1) . A distal locus is deleted in the 5qÀ syndrome, and a proximal locus is deleted in patients with higher risk MDS that commonly involves other cytogenetic abnormalities. Most patients have large deletions that encompass both CDRs. However, a small number of patients have highly informative deletions in which only one CDR is deleted, allowing the CDRs to be distinguished and narrowed.
The CDR for the 5qÀ syndrome was defined by Boultwood and colleagues. [23] [24] [25] Using fluorescence in situ hybridization and molecular mapping approaches, these investigators identified a 1.5-megabase locus at 5q32-5q33. Among the genes in this interval, 33 are expressed in CD34 þ hematopoietic progenitor cells, a population that includes the cells that are transformed in MDS. Multiple patients with the 5qÀ syndrome have been reported who have deletions in which the proximal boundary excludes the 5q31 CDR described below. 24, 25 A distinct CDR has been defined at 5q31 in patients with MDS or AML with 5q deletions who do not have the 5qÀ syndrome. [26] [27] [28] This deletion is also seen in patients with therapy-related MDS or AML, and is often associated with additional cytogenetic abnormalities. Multiple candidate tumor suppressor genes are contained within this locus, including EGR1, CDC25C and CTNNA1. [26] [27] [28] In addition to the two CDRs, the long arm of chromosome 5 contains a fascinating array of genes that are relevant to hematopoiesis and malignancy. Numerous cytokine genes are located on 5q, including a cluster at 5q31 encoding interleukins 3, 4, 5, 9, 13 and 17b, and granulocyte-monocyte colonystimulating factor. A subset of these cytokine genes is located in a tight cluster on 5q31. In addition, the genes encoding several cytokine receptors are located on 5q, including colonystimulating factor 1 receptor, platelet-derived growth factor receptor-a (PDGFRA), and platelet-derived growth factor receptor-b (PDGFRB). Two of these receptor tyrosine kinases are aberrantly activated by translocations in myeloproliferative diseases: TEL-PDGFRB in chronic myelomonocytic leukemia and FIP1L1-PDGFRA in hypereosinophilic syndrome. 29, 30 Functional dissection of the 5qÀ syndrome CDR The absence of evidence for homozygous inactivation of any genes within the 5qÀ syndrome CDR, despite extensive efforts, raises the possibility that the disease is caused by haploinsufficiency for one or more genes. This possibility has been reinforced by the demonstration that some tumor suppressors, including PAX5, are haploinsufficient in some human leukemias. 31 Similarly, haploinsufficiency for RUNX1 causes a platelet disorder with predisposition to leukemia. 32 As 5q deletions in MDS are uniformly large, and the intact allele has no apparent abnormalities, genetic studies may be incapable of identifying a critical haploinsufficiency disease gene. RNA interference offers an alternative approach, enabling the functional interrogation of each gene within a CDR.
The 5qÀ syndrome is well suited for a functional screen. Deletion of a defined chromosomal segment leads to a highly consistent clinical phenotype; and this clinical phenotype, ineffective production of erythrocytes from hematopoietic progenitor cells with relative preservation of platelet and neutrophil generation, can be modeled in vitro.
A systematic RNA interference screen, targeting each of the genes in the 5qÀ syndrome CDR in normal human hematopoietic progenitor cells, revealed that decreased expression of one gene, RPS14, recapitulates the hematologic phenotype of the 5qÀ syndrome in vitro. 33 In normal progenitor cells, multiple different RPS14 shRNAs powerfully decreased the ratio of erythroid to megakaryocytic cells produced in vitro, decreased the ratio of erythroid to myeloid cells and caused apoptosis of differentiating erythroid cells. In hematopoietic progenitor cells from patients with the 5qÀ syndrome, forced expression of RPS14 with a lentiviral cDNA expression vector rescued the erythroid defect, validating the functional importance of RPS14. 33 The level of RPS14 gene expression and lack of aberrant promoter methylation in bone marrow cells from Table 1 The World Health Organization criteria for the 5qÀ syndrome
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Peripheral blood
Bone marrow Figure 1 Schema of 5q deletion in MDS. The segment of chromosome 5q that is involved in variably sized MDS deletions includes two commonly deleted regions, a cluster of cytokine genes and the NPM1 gene. The distal CDR, associated with the 5qÀ syndrome, contains the RPS14 gene. The proximal CDR contains the CTNNA1 and EGFR1 genes. CDR, common deleted region; MDS, myelodysplastic syndrome.
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BL Ebert patients with the 5qÀ syndrome support the model of RPS14 as a haploinsufficiency disease gene.
33-35
RPS14, a universally expressed core component of the 40S ribosomal subunit, is an unexpected disease gene for such a specific phenotype. However, inherited mutations for several ribosomal protein genes cause Diamond-Blackfan anemia (DBA), a rare congenital disorder that is also characterized by a severe macrocytic anemia, including RPS19 amd RPS24.
36-39
Somatic deletion of one RPS14 allele in the 5qÀ syndrome, or congenital mutation of one RPS19 allele in DBA, leads to a defect in 18S rRNA processing and 40S ribosomal subunit formation. 33, 40, 41 The same defect in erythropoiesis is also observed in DBA patients with RPL35a mutations, although these mutations are associated with defects in 60S ribosomal subunit formation. 42 The pathophysiology of several other bone marrow syndromes has been linked to the defects in ribosomal biogenesis, including Shwachman-Diamond syndrome, cartilage hair hypoplasia and dyskaratosis congenita. 43 Animal models have provided insight into the mechanistic basis for ineffective erythropoiesis caused by the deletion or mutation of one allele of a ribosomal protein gene in the 5qÀ syndrome or DBA. Mice with mutations in RPS19 develop anemia as do zebrafish with decreased expression of RPS19.
44-46
In both mice and zebrafish, RPS19 deficiency leads to p53 accumulation. 44, 45 In mice, p53 inactivation rescues the anemia. 45 Interestingly, zebrafish with haploinsufficiency for many different ribosomal protein genes develop cancer with high penetrance, consistent with the predisposition to developing cancer in DBA. 47 In aggregate, these animal models show that haploinsufficiency for ribosomal genes causes ineffective erythropoiesis, activation of p53 that is important for the erythroid defect and a predisposition to cancer in zebrafish.
Identifcation of other candidate genes on 5q
The phenotype of MDS patients with 5q deletions varies widely. Only a minority of patients have the 5qÀ syndrome. RPS14 deficiency cannot account for the full clinical spectrum, and may not account for aspects of the 5qÀ syndrome, including the clonal advantage of MDS cells and the striking response of 5qÀMDS to lenalidomide. Multiple other genes on 5q have been implicated in the pathogenesis of myeloid malignancies. Although the manner in which these genes interact has not been determined, it is likely that the phenotype of MDS is influenced by the deletion of multiple 5q genes.
Heterozygous deletion causes a decreased gene dosage for the deleted genes, but may not result in a decrease in gene expression to 50% of wild-type levels. Homeostatic mechanisms may correct expression to normal levels, deletion of adjacent genes and micro-RNAs may alter the expression of some deleted genes and epigenetic modifications can alter the expression of some genes. The expression of RPS14 appears to be truly haploinsufficient and is not altered by epigenetic mechanisms. [33] [34] [35] In addition, the expression of several other genes on 5q, located in the proximal or distal CDRs (Figure 1) , are also decreased to approximately 50%, including the genes encoding CTNNA1, CDC25C, PP2A and SPARC. 48, 49 The expression of CTNNA1 in some cases of MDS and AML with 5q deletions in leukemia stem cells (
is much lower than that in a similar population of cells from patients without 5q deletions. 49 In HL-60 cells, a myeloid leukemia cell line that harbors a 5q deletion, the remaining CTNNA1 allele is epigenetically silenced by methylation and histone deacetylation. Increased expression of CTNNA1 in HL-60 cells causes apoptosis and decreased proliferation. Therefore, CTNNA1 may act as a classical tumor suppressor in some cases of MDS or AML in which one allele is deleted and the other is epigenetically silenced. 49 Response to lenalidomide, another hallmark of 5q deletions in MDS, may be due to the severity of the block in erythroid differentiation, and the ability of lenalidomide to induce erythroid differentiation. 50 Lenalidomide causes selective apoptosis of 5q-deleted cells associated with a G 2 cell cycle arrest. Two phosphatases on 5q, CDC25C and PP2A regulate the cell cycle, and expression of both genes is decreased in cells with 5q deletions. The biochemical activity of both phosphatases is inhibited by lenalidomide. Moreover, genetic targeting of CDC25C and PP2A by RNA interference decreases expression of the genes to mimic haploinsufficiency and promote apoptosis in response to lenalidomide treatment. These data indicate that these two phosphatases that regulate the cell cycle may contribute to the lenalidomide sensitivity of MDS cells with 5q deletions. 48 The SPARC gene is a candidate tumor suppressor within the CDR with decreased expression in CD34 þ cells with 5q deletions. Of note, the expression of SPARC is increased in response to lenalidomide treatment. 51 Homozygous knockout of the SPARC gene in mice causes thrombocytopenia and a decreased hematocrit. Methylcellulose colony formation of hematopoietic cells is altered in SPARC null mice with decreased burst-forming unit erythroid colonies and normal erythroid colony-forming units and granulocyte/monocyte colony-forming units. 52 While the functional role of SPARC in hematopoiesis has been examined most closely in SPARC null mice, mutations of the intact SPARC allele do not occur in MDS patients with 5q deletions.
53
EGR1 is a zinc-finger transcription factor and is one of the genes in the proximal CDR on 5q. Murine models support a role for EGR1 haploinsufficiency in MDS. Mice with EGR1 haploinusufficiency develop myeloid malignancies at a higher rate than wild-type mice when treated with a mutagen, N-ethylnitrosourea (ENU). 54 Malignancies arising from ENU treatment in EGR1 haploinusfficient mice do not have mutations in the remaining EGR1 allele. 54 EGR1 is a critical regulator of stem cell quiescence and retention of stem cells in the bone marrow stem cell niche, and its deletion may contribute to the clonal advantage of stem cells containing the 5q deletion.
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NPM1
Although not contained within either CDR on 5q, NPM1 is deleted in many cases of 5qÀ MDS with large chromosomal deletions. NPM1 is the most commonly mutated gene in cytogenetically normal AML, occurring in 35% cases of primary AML. 56 Targeted knockout of one allele of NPM1 leads to genetic instability in vitro and in vivo. [57] [58] [59] Mouse embryo fibroblasts from NPM þ /À mice develop supernumerary centrosomes and aneuploidy. NPM1 heterozygous mice expressing c-Myc under the control of immunoglobin heavy chain enhancer (Em-Myc) develop lymphomas more rapidly and with more chromosomal abnormalities than mice with wild-type NPM1.
57 NPM1 haploinsufficient mice develop both myeloid and lymphoid malignancies, with retention of the wild-type NPM1 in malignant cells, showing that NPM1 is a haploinsufficient tumor suppressor in hematopoietic cells. 59 The hematologic phenotype of NPM1 heterozygous mice has similarities to human MDS. 57 Although red blood cell counts and hemoglobin are normal, the mean corpuscular volume of red blood cells is increased. The bone marrows of these mice are hypercellular,
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Deletion 5q in myelodysplastic syndrome BL Ebert with evidence of dyspasia of the erythroid and megakaryocytic lineages, and an accumulation of immature erythroid cells. 57 These findings indicate that decreased gene dosage for NPM1 in patients with large 5q deletions contributes to the phenotype of MDS.
Conclusions and future directions
Fundamental insights into the molecular basis of cancer have been made through the identification of genes that are altered or dysregulated by balanced chromosomal translocations, intragenic mutations, homozygous deletions, focal amplifications and epigenetic modifications. Among the myeloid malignancies, for example, the identification of chromosomal translocations and mutations within tyrosine kinase and other genes have helped elucidated the biology of these diseases, leading ultimately to the development of novel targeted therapies. In contrast, key genes and pathways that are affected by large monoallelic deletions and broad chromosomal amplifications and genetic lesions that are commonly found in MDS patients have been difficult to identify. The 5q deletion in MDS is a paradigm for the molecular dissection of a large heterozygous chromosomal deletion in cancer. Recent evidence indicates that multiple genes may have functional roles. Anemia, thrombocytosis, clonal dominance and response to lenalidomide may be caused by the cooperative effects of haploinsufficiency for multiple genes. Functional approaches have been, and will continue to be, central to the investigation of the 5q deletion.
As an increasing number of genes on 5q are reported to contribute to MDS, important goals of future work will be to validate the roles of individual genes, and to explore how haploinsufficiency for multiple genes may act in a cooperative fashion. RNA interference will allow the systematic analysis of many genes, either individually or in combinations, in a uniform assay. The rescue of specific aspects of the MDS phenotype by overexpression of a single gene in hematopoietic progenitor cells from MDS patients with 5q deletions will provide powerful genetic validation for key genes. Murine models, though not always reflective of the human phenotype, will be a critical component of future studies.
The methodologies that are being employed to dissect the 5q deletion are not unique to MDS. Other recurrent heterozygous deletions have been described in hematologic malignancies and solid tumors. The development of increasingly sophisticated assay systems will enable the application of RNA interferencebased screens to identify critical haploinsufficiency disease genes in cancer.
